



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,

Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585

E-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

10th November, 2023.

To,
The General Manager,
Listing Department,
BSE Limited,
P.J. Towers,
Dalal Street Fort,
Mumbai-400001.

Sub: Unaudited Financial Results for the quarter and half year ended 30th September, 2023 – Regulation 33 (3) (a).


Ref: Company Scrip Code: 524711


With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Friday, 10th November, 2023 at 04:00 PM. And concluded at 05:55 P.M at the corporate office of the Company, interalia, considered and approved the unaudited Financial Results for the quarter and half year ended 30th September, 2023.

Copy of un-audited Financial Results for the quarter and half year ended 30th September, 2023 along with Limited review Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,
For Vista Pharmaceuticals Limited


DHANANJAYA ALLI
WHOLETIME DIRECTOR
DIN: 00610909



VISTA PHARMACEUTICALS LIMITED

CIN:L24239TG1991PLC012264

Statement of Unaudited Financial Results for the Quarter and Half Year ended 30th September,2023

(in Rs Lakhs)

S.No	Particulars	Quarter ended			Half- Year ended		Year ended
		September 30,2023	June 30,2023	September 30,2022	September 30,2023	September 30,2022	March 31,2023
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Income						
	a. Revenue from operations	346.98	198.10	0.00	545.08	0.00	100.37
	b. Other income	7.97	13.21	0.00	21.17	0.00	39.94
2	Total Income (a+b)	354.94	211.31	0.00	566.25	0.00	140.31
3	Expenses						
	a) Cost of Material Consumed	311.29	206.37	0.00	517.66	0.00	282.84
	b) Change in Inventories	9.46	(9.46)	-	0.00	0.00	-
	c) Employee benefits expense	44.52	41.73	2.60	86.25	7.70	50.87
	d) Finance costs	31.82	32.67	25.70	64.48	49.48	121.35
	e) Depreciation and amortization expense	18.24	17.34	15.40	35.58	30.80	61.76
	f) Other expenses	74.08	51.56	12.25	125.64	27.30	211.12
	g) Prior Period Expenses	24.41	-	-	24.41	0.00	0.00
	Total Expenses	513.82	340.21	55.95	854.03	115.28	727.94
4	Profit before tax (2-3)	(158.88)	(128.91)	(55.95)	-287.78	-115.28	-587.63
5	Tax expense						
	(1) Current tax	0.00	0.00	-	0.00	0.00	0.00
	(2) Deferred tax	43.05	(33.45)	(31.96)	9.60	-32.26	83.83
	(3) Previous year income tax adjustment						-105.26
6	Net Profit for the Period (4-5)	(201.93)	(95.46)	(23.99)	-297.39	-83.02	(566.20)
7	Other comprehensive income (OCI)						
	(a) (i) Items that will not be reclassified to profit or loss	0.31	0.12	-	0.43	-	(0.25)
	(ii) Tax on items that will not be reclassified to profit or loss	0.00	-	-	-	-	-
	(b) (i) Items that will be reclassified to profit or loss	0.00	-	(7.24)	-	(15.80)	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	-	-	-	-	-
	Total Other Comprehensive income	0.31	0.12	(7.24)	0.43	(15.80)	(0.25)
8	Total Comprehensive income (6+7)	(201.62)	(95.34)	-31.23	-296.96	-98.82	-566.46
	Earnings per equity share (Face value of Rs.2/- each)						
	(1) Basic	(0.46)	-0.23	-0.08	-0.72	-0.27	-1.54
	(2) Diluted	(0.34)	-0.15	-0.08	-0.49	-0.27	-0.90
	Paid- up equity share capital(Face Value of Rs.2/- each)	883.83	855.34	735.88	883.83	735.88	751.13

Notes:

- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules, 2016.
- The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 10th November, 2023
- The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- Total income for the current quarter reported Rs 354.94 Lakhs compared to Rs. NIL for the corresponding quarter of the previous year.
- The Loss before tax for the current quarter is Rs.158.88 Lakhs compared to Loss Before tax of Rs. 55.95 Lakhs for the corresponding quarter of the previous year.
- The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products. Hence, segmental reporting as per IND AS-108 is not made.
- The results for the quarter ended 30th September 2023 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.
- Figures for the previous periods /year have been regrouped/reclassified wherever necessary.

Place Hyderabad
Date:10.11.2023

For Vista Pharmaceuticals Limited

Dhananjay

Dhananjay Alli
Whole time Director
(DIN: 00610909)



VISTA PHARMACEUTICALS LIMITED

Registered Office : Gopalaipalli(Village),Narketpalli(Mandal),Nalgonda Dist.T.S. - 508254

(CIN: L24239TG1991PLC012264)

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 30th Sep, 2023

(Rs.in Lakhs)

Particulars	September ,2023	March ,2023
Cash Flows from Operating Activities		
Net profit before tax	(287.78)	(587.63)
Adjustments for :		
Depreciation and amortization expense	35.58	61.76
Unrealised Foreign Exchange Gain/Loss	-	(1.42)
Gain on investments carried at fair value through profit or loss	0.43	1.16
Interest & Finance Charges Paid	64.48	121.35
Operating profit before working capital changes	(187.28)	(404.78)
Movements in Working Capital		
(Increase)/Decrease in Inventories	(48.93)	165.08
(Increase)/Decrease in Other financial assets	0.00	0.00
(Increase)/Decrease in Trade Receivables	(3.28)	(78.68)
(Increase)/Decrease in Other Current Assets	30.08	(91.99)
(Increase)/Decrease in Other Non Current Assets	9.05	(43.71)
Increase/(Decrease) in Trade Payables	(69.35)	243.60
Increase/(Decrease) in Other financial liabilities	0.00	0.00
Increase/(Decrease) in Other Current liabilities	(23.22)	(76.93)
Increase/(Decrease) in Other Non Current liabilities	0.00	0.00
Increase/(Decrease) in Provisions	0.00	11.02
Changes in Working Capital	(105.66)	128.38
Cash generated from operations	(292.94)	(276.40)
Direct Taxes Paid	-	105.26
Net Cash from operating activities (A)	(292.94)	(171.14)
Cash flows from Investing Activities		
Purchase of Fixed Assets (Including CWIP)	(52.78)	(127.05)
Intangible Assets	0.00	0.00
Net Cash used in Investing Activities	(52.78)	(127.05)
Cash flows from/(used in) Financing Activities		
Issue of Share Capital	663.49	76.27
Issue of Share Warrants	(179.17)	615.66
Proceeds from Long term borrowings	(112.32)	(224.65)
Repayment/Proceeds of/from Short-term borrowings	42.02	(34.56)
Interest paid	(64.48)	(121.35)
Net Cash used in Financing Activities	349.54	311.38
Net Increase/(Decrease) in cash and cash equivalents	3.81	13.19
Cash and Cash equivalents at the beginning of the year	20.39	7.19
Cash and Cash equivalents at the ending of the year	24.20	20.39

FOR VISTA PHARMACEUTICALS LIMITED

Place:Hyderabad

For Vista Pharmaceuticals Limited

Date:10.11.2023

Dhananjay Ali
Whole time Director
(DIN: 00610909)

VISTA PHARMACEUTICALS LIMITED
CIN:L24239TG1991PLC012264
STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Rs. In lakhs)

S No	Particulars	As at 30th September 2023	As at 31st March 2023
		(Un Audited)	(Audited)
I.	ASSETS		
	Non-current assets		
(a)	Property, Plant and Equipment	1,004.22	1,018.52
(b)	Capital work-in-progress	964.37	932.87
(c)	Intangible assets	955.30	955.30
(d)	Financial Assets		
	(i) Investments	2.14	1.71
	(ii) Other Financial Assets	13.15	12.63
(e)	Deferred tax assets (Net)	254.76	264.36
(f)	Other Non-Current Assets	32.50	42.50
	Total Non - Current Assets	3,226.45	3,227.90
	Current assets		
(a)	Inventories	816.61	767.68
(b)	Financial assets	-	-
	(i) Investments	-	-
	(ii) Trade receivables	1,128.37	1,125.09
	(iii) Cash and Bank equivalents	24.20	20.39
	(iv) cash and cash equivalent (other than above)	-	-
(c)	Other current assets	431.83	461.90
	Total Current Assets	2,401.00	2,375.06
	Total Assets	5,627.44	5,602.95
II	EQUITY AND LIABILITIES		
	Equity		
(a)	Equity Share capital	883.83	751.13
(b)	Other equity	2,974.30	2,919.63
	Total Equity	3,858.13	3,670.77
	Liabilities		
	Non-current liabilities		
(a)	Financial Liabilities		
	(i) Borrowings	405.61	517.93
	(ii) Other financial liabilities	-	-
(b)	Deferred tax liabilities (Net)	-	-
(c)	Provisions	6.02	6.02
	Total Non - Current Liabilities	411.63	523.95
	Current liabilities		
(a)	Financial Liabilities		
	(i) Borrowings	520.00	477.97
	(ii) Trade payables	710.91	780.26
	(iii) Other financial liabilities	5.30	5.30
(b)	Current Tax Liabilities (Net)	-	-
(c)	Provisions	35.80	35.80
(d)	Other current liabilities	85.68	108.90
	Total Current Liabilities	1,357.68	1,408.23
	Total Equity and Liabilities	5,627.45	5,602.95

FOR VISTA PHARMACEUTICALS LIMITED

Place:Hyderabad
Date:10.11.2023

For Vista Pharmaceuticals Limited

Dhananjay

Dhananjay Alli
Whole time Director
(DIN: 00610909)






Independent Auditor's Review Report on unaudited Quarterly Financial results of VISTA PHARMACEUTICALS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Vista Pharmaceuticals Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Vista Pharmaceuticals Limited ("the Company") for the quarter ended and Six months ended September 30, 2023 ("the Statement ") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to



obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY

Chartered Accountants

Firms Registration No : 009068S



D.Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 23209211BGYWMW7412

Place: Hyderabad

Date: November 10, 2023





Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Date: 10/11/2023

To
The General Manager,
Listing Department,
BSE LIMITED
Dept. of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001

Dear Sirs/Madam,

Subject: Declaration pursuant to Regulation 33 (3) (d) of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Company Scrip Code: 524711

DECLARATION

I, Dhanajaya Alli, Whole time Director of VISTA PHARMACEUTICALS LTD (CIN: L24239TG1991PLC012264) having its Registered office at APIIC, Industrial Estate Gopalaipalli V, Marketpalli Mandal, Plot no 10 to 14 & 16 to 20, Nalgonda, Telangana, 508254 hereby declare that, the Statutory Auditors of the Company, M/s. A.M REDDY & D.R REDDY (FRN: 009068S), have issued an Limited Review report with an unmodified opinion on un audited Financial Results of the Company for the quarter and half year ended 30th September 2023.

This Declaration is given in compliance to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulation, 2016 vide notification No. SEBI/LADNRO/GN/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take this declaration on your records.

Thanking You,

Yours Sincerely,
for VISTA PHARMACEUTICALS LTD.

DHANAJAYA ALLI
WHOLE TIME DIRECTOR
DIN: 00610909
Date: 10.11.2023





Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,

Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585

E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

Date: 10.11.2023

To
The Board of Directors
Vista Pharmaceuticals Limited

Dear All,

Sub: Certificate under 33(2) (a) of SEBI (LODR), 2015

This is to certify that the un-audited financial results for the quarter and year ended 30thSeptember, 2023, as placed before the Board, do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

Thanking you,

for Vista Pharmaceuticals Limited


Suneel Pachipala
Chief Financial Officer

